Skip to main content
Equibles
ABEO logo

ABEO · Abeona Therapeutics Inc.

Track ABEO — free Ask ALVIS about ABEO
$6.00 -0.03 (-0.42%)
Market Cap
$343.11M
Shares
57.00M

Abeona Therapeutics Inc. Earnings Call Transcripts

Every quarterly earnings call for Abeona Therapeutics Inc. (ABEO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $346,000 −$22.04M '22 Q1 22-05-13 · $1.00M −$4.10M '22 Q2 22-08-11 · $ −$7.12M '22 Q4 23-03-29 ▲250% $3.50M −$16.65M '23 Q2 23-08-08 ▲160% $3.50M −$11.84M '23 Q3 23-11-13 · $400,000 $108.83M '25 Q2 25-07-02 · $400,000 −$5.16M '25 Q3 25-11-12 LATEST · $8.72M −$17.07M '26 Q1 26-05-13
Annual General Meeting
Investor event
2026-06-12
Annual Meeting of Stockholders
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Abeona Therapeutics Inc. Q1 FY2026 Earnings Call
Revenue
$8.72M
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-17
Full Year 2025 Results and Business Update Conference Call
Positive tone ZivaSkin launch execution and patient cadence QTC onboarding and site footprint expansion Payor coverage and market access
Results not yet reported
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-03-10
2026 Leerink Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-12
Abeona Therapeutics Inc. Q3 FY2025 Earnings Call
Positive tone ZivaSkin commercial launch progress Qualified treatment center (QTC) network expansion Patient identification and demand
Revenue
$400,000
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-02
Abeona Therapeutics Inc. Q2 FY2025 Earnings Call
Confident tone ZEVASKYN FDA approval and commercial launch Patient demand and QTC activation Payer coverage and reimbursement
Revenue
$400,000
Diluted EPS
$1.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Abeona Therapeutics Inc. Q1 FY2025 Earnings Call
Confident tone Patient demand and Abeona Assist ZEVASKYN FDA approval and commercial launch Qualified Treatment Centers and patient activation
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Abeona Therapeutics Inc. Q4 FY2024 Earnings Call
Confident tone Launch readiness and qualified treatment centers pz-cel PDUFA and FDA approval PRV (Priority Review Voucher)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Abeona Therapeutics Inc. Q3 FY2024 Earnings Call
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Abeona Therapeutics Inc. Q2 FY2024 Earnings Call
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Abeona Therapeutics Inc. Q1 FY2024 Earnings Call
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Abeona Therapeutics Inc. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Abeona Therapeutics Inc. Q3 FY2023 Earnings Call
Revenue
$3.50M
▲ 160% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Abeona Therapeutics Inc. Q2 FY2023 Earnings Call
Revenue
$3.50M
▲ 250% YoY
Diluted EPS
$-0.92
▼ 167.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Abeona Therapeutics Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
Abeona Therapeutics Inc. Q4 FY2022 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-08-11
Abeona Therapeutics Inc. Q2 FY2022 Earnings Call
Revenue
$1.00M
Diluted EPS
$1.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
Abeona Therapeutics Inc. Q1 FY2022 Earnings Call
Revenue
$346,000
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Abeona Therapeutics Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Abeona Therapeutics Inc. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Abeona Therapeutics Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-18
Abeona Therapeutics Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-24
Abeona Therapeutics Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Abeona Therapeutics Inc. Q3 FY2020 Earnings Call
Revenue
$7.00M
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Abeona Therapeutics Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Abeona Therapeutics Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Abeona Therapeutics Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 318306 CUSIP 00289Y206 13F (30d) 16 filings 16 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)